OpenMFM · Clinical Education
Prenatal genetics

Possible 47,XXY
on NIPT

From screening signal to informed, patient-centered management

Dr. Chukwuma Onyeije · Maternal-Fetal Medicine
Use ← → or space01 / 22
Clinical frame
Screen ≠ diagnosis

A high-risk NIPT result is not a fetal diagnosis.

Pause
→
Verify
→
Counsel
→
Offer diagnosis

Do not make irreversible decisions from cfDNA alone.

ACOG PB 226 · SMFM CS #7402 / 22
Biology

NIPT analyzes mostly placental DNA.

It does not directly sample fetal cells.

P

Placenta

cfDNA signal
⇄
F

Fetus

May differ
Fetal XXYPlacental mosaicismMaternal signalVanished twin
Wilkins-Haug & Reimers, 202303 / 22
First visit

Four priorities at the first consultation

01Verify the report
02Estimate probability
03Arrange genetics
04Discuss diagnosis

Ultrasound informs context; it cannot confirm or exclude 47,XXY.

Immediate management04 / 22
Pre-interpretation check

Verify before interpreting

Laboratory method
Reported PPV
Fetal fraction
Gestational age
Twins or vanished twin
Donor egg or transplant
Ultrasound sex
Prior cytogenetics
Patient goals
Immediate management05 / 22
Probability

PPV is patient- and laboratory-specific.

Use the report’s estimate when available. Avoid presenting one number as universal.

74%ACMG pooled PPV
for 47,XXY
ACMG evidence-based NIPS guideline, 202306 / 22
Shared decisions

Center the patient’s values

CertaintyInformation desired
TimingWhen answers matter
ProcedureRisk preferences
DecisionsPotential impact
PlanningNewborn preparation
ACOG PB 22607 / 22
Diagnostic testing

Two diagnostic pathways

CVS
10–13+6
weeks
Placental tissue
Amniocentesis
≥15
weeks
Fetal amniocytes

Both require informed procedural counseling.

Procedure choice is individualized08 / 22
Diagnostic nuance

Choose the tissue deliberately

↞

Earlier answer

CVS may provide information sooner.

VS
◎

Less placental ambiguity

Amniocentesis samples fetal cells.

Neither choice should be reduced to a slogan.

Wilkins-Haug & Reimers, 202309 / 22
Cytogenetics

Build the laboratory plan

KaryotypeChromosome count and mosaicism
→
Rapid assayOptional preliminary result
→
MicroarrayWhen clinically indicated

Coordinate testing with genetics and cytogenetics.

Diagnostic confirmation10 / 22
Imaging

Ultrasound has a defined role.

Complete gestation-appropriate imaging and a detailed anatomy survey. Escalate only for additional fetal or obstetric findings.

∿
Cannot confirm XXY
Prenatal phenotype is often nonspecific11 / 22
Discordant result

If diagnostic testing is normal

Review biology

Placental mosaicism
vanishing twin

Discordant
result

Review context

Assay limits
maternal signal

Additional evaluation should be individualized.

Interpretation12 / 22
Confirmed 47,XXY
Variable expression

Outcome remains highly variable.

Many individuals have typical appearance and intelligence. Prenatal testing cannot predict one child’s developmental, endocrine, or fertility outcome.

White et al., 202213 / 22
Phenotype counseling

Potential—not inevitable—features

Language or learning differences
Motor or executive challenges
Taller stature
Smaller testes or hypogonadism
Reduced fertility
Bone or metabolic health risks
Use prospectively ascertained data when available14 / 22
Antenatal care

Pregnancy care stays obstetric.

1Routine careStandard prenatal plan
2AnatomyDetailed survey
3SurveillanceWhen indicated
4DeliveryObstetric indications

47,XXY does not dictate delivery.

Pregnancy management15 / 22
Patient autonomy

If prenatal diagnosis is declined

Respect informed refusal and preserve future options.

1

Continue routine obstetric care

2

Document counseling

3

Offer postnatal karyotype

ACOG PB 22616 / 22
Life-course care

Plan support after birth

NewbornPediatrics
+ genetics
InfancyDevelopmental surveillance
ChildhoodTherapy when indicated
PubertyPediatric endocrinology
AdolescenceFertility counseling

Surveillance should be proactive—not presumptive.

EAA Klinefelter guideline, 202117 / 22
Endocrine care

Avoid automatic infant treatment

Routine neonatal testosterone is not established. Refer to pediatric endocrinology and individualize treatment to clinical evidence.

NO
AUTOMATIC
THERAPY
EAA Klinefelter guideline, 202118 / 22
Communication

Language shapes decisions

Say
“This screen raises the chance of 47,XXY.”
Accurate while uncertainty remains
Avoid
“Your baby has Klinefelter syndrome.”
Premature diagnostic language
Patient-centered counseling19 / 22
One-page algorithm

Clinical pathway

High-risk
47,XXY NIPT
→
Verify
+ counsel
→
CVS or
amniocentesis

Not confirmed

Review discordance

↔

Confirmed

Balanced counseling
+ routine obstetric care

Management summary20 / 22
Take-home

Three actions protect patients

01

Do not diagnose from NIPT.

02

Offer genetics-guided diagnostic testing.

03

Counsel with balanced life-course evidence.

Clinical essentials21 / 22
Evidence base

Key references

ACOG Practice Bulletin 226Screening for Chromosomal Abnormalities · 2020
SMFM Consult Series #74Updated prenatal genetic screening guidance · 2025
ACMG Evidence-Based GuidelineNoninvasive prenatal screening · 2023
Wilkins-Haug & ReimersDiagnostic testing after positive SCA cfDNA · 2023
White et al.What should we tell prospective parents? · 2022
EAA Klinefelter GuidelineLife-course management · 2021
Educational use; apply individualized clinical judgment22 / 22
← → navigate · R references · F fullscreen · Home/End jump
← OpenMFM Library